Sanofi adds to SoloStar® platform, with highest-capacity long-acting insulin pen injector on the market
Published on: 17th October 2018
Sanofi have recently launched the Toujeo® Max SoloStar® pen injector in the US, adding another device to the multi-award winning SoloStar® platform.
It has a capacity of 900 insulin units, the largest of any long-acting insulin pen on market, and an increased maximum dose of 160 units. This means fewer pen changes and fewer injections, making life easier for the increasing number of patients on higher insulin doses. DCA partnered Sanofi throughout the development of Toujeo® Max SoloStar®, achieving a rapid launch schedule and a high level of manufacturing efficiency.
